SRINAGAR: Russia has announced a breakthrough in the fight against cancer: a personalised mRNA-based vaccine named Enteromix, which has shown striking tumour-fighting results in early trials. Developed by the country’s Federal Medical and Biological Agency (FMBA), the vaccine reportedly demonstrated 100 per cent efficacy in preclinical studies and has now advanced through initial human testing, igniting global attention but also caution from the scientific community.
The announcement was made at the 10th Eastern Economic Forum in Vladivostok earlier this month, where FMBA chief Veronika Skvortsova described the vaccine as a potential “revolution” in oncology. She said the first version of Enteromix, tailored for colorectal cancer, is awaiting approval from Russia’s Ministry of Health. “This is the outcome of years of mandatory preclinical trials, and we have proven both safety and efficacy in early phases,” Skvortsova told participants.
Enteromix is based on mRNA technology, the same platform that powered several COVID-19 vaccines, but with a far more personalised approach. Instead of preventing disease in healthy individuals, it is designed to treat patients who already have cancer. By using a patient’s unique RNA profile, scientists create a customised vaccine that trains the immune system to recognise tumour antigens and destroy cancer cells.
Unlike chemotherapy, which indiscriminately damages both healthy and malignant tissue, Enteromix aims to selectively target tumours. Russian researchers said trials with 48 volunteers showed that the vaccine could shrink tumours or slow their growth by 60 to 80 per cent, depending on cancer type. It was also safe for repeated administration and did not produce the harsh side effects typically associated with radiation or chemotherapy.
The early focus is colorectal cancer, one of the world’s deadliest forms, but researchers are also working on versions for glioblastoma—a highly aggressive brain tumour—and melanomas, including ocular melanoma.
Russia is not alone in pursuing cancer vaccines. The UK’s National Health Service has launched the Cancer Vaccine Launch Pad to accelerate personalised mRNA trials, with thousands of patients expected to be enrolled by 2030. In the US, biotech companies such as Moderna and BioNTech are running advanced Phase II and III trials for cancers of the pancreas, lung, and melanoma. The FDA has so far approved only one cancer vaccine—Sipuleucel-T for prostate cancer in 2010—which extended survival modestly but did not transform treatment.
India, too, is stepping into this frontier. Earlier this year, the government announced plans for a vaccine targeting breast, oral, and cervical cancers for girls aged 9 to 16. Separately, it has already rolled out an affordable HPV vaccine to curb cervical cancer among women.
Despite Russia’s bold claims, oncologists worldwide are urging caution. Experts stress that while the results are promising, the sample size of 48 patients is too small to draw sweeping conclusions.
The Union Health Ministry has said it is closely tracking developments. A senior official confirmed to ETV Bharat that both the Department of Health and the Indian Council of Medical Research (ICMR) are monitoring the situation, but cautioned that it was “too early to comment.”
For any foreign vaccine to be introduced in India, manufacturers must secure approval from the Central Drugs Standard Control Organisation (CDSCO). While some pathways were relaxed during the COVID-19 pandemic for vaccines cleared by regulators such as the US FDA or listed by the WHO, new entrants must still meet Indian safety and quality benchmarks.
This could be a stumbling block for Enteromix. Russia’s earlier vaccine, Sputnik V for COVID-19, faced widespread criticism for being approved before completing Phase III trials. International scepticism, coupled with delays in data transparency, significantly hampered its acceptance, and even in India, it accounted for less than 1 per cent of total COVID-19 vaccinations.
For now, Enteromix remains in its infancy. Phase I data indicates safety and potential efficacy, but much larger multi-centre trials will be needed to prove its worth across diverse populations. If it succeeds, Russia could become the first country to introduce a truly personalised mRNA cancer vaccine.
“mRNA cancer vaccines are one of the most promising fields in oncology today,” said Professor Siow Ming Lee of University College London Hospitals in The Guardian. “We are entering an exciting era where treatments can be tailored to the unique profile of each patient’s tumour.”
Whether Enteromix fulfils that promise will depend on rigorous validation, transparent data sharing, and global regulatory acceptance. For patients battling some of the most aggressive cancers, the stakes could not be higher.
